Information Provided By: 
Fly News Breaks for July 27, 2016
ABT, STJ
Jul 27, 2016 | 07:38 EDT
Oppenheimer analyst Steven Lichtman went to Not Rated on St. Jude Medical (STJ) from his previous Perform rating due to its acquisition by Abbott (ABT).
News For STJ;ABT From the Last 2 Days
ABT
Apr 18, 2024 | 21:44 EDT
ABT
Apr 18, 2024 | 09:14 EDT
RBC Capital lowered the firm's price target on Abbott to $125 from $128 but keeps an Outperform rating on the shares. The analyst states that despite a strong Q1 with 10.8% underlying revenue and double-digit EPS growth, the stock was down 3%, which reflects sentiment on the broader MedTech space, where high expectations require a beat and raise for stocks to be rewarded. RBC maintains however that it sees upside potential for Abbott "as 2024 drivers take hold".
